Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.

Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.

Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies,...

Full description

Bibliographic Details
Main Authors: Daniel Y Zhu, Matthew J Gorman, Dansu Yuan, Jingyou Yu, Noe B Mercado, Katherine McMahan, Erica N Borducchi, Michelle Lifton, Jinyan Liu, Felix Nampanya, Shivani Patel, Lauren Peter, Lisa H Tostanoski, Laurent Pessaint, Alex Van Ry, Brad Finneyfrock, Jason Velasco, Elyse Teow, Renita Brown, Anthony Cook, Hanne Andersen, Mark G Lewis, Douglas A Lauffenburger, Dan H Barouch, Galit Alter
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-05-01
Series:PLoS Biology
Online Access:https://doi.org/10.1371/journal.pbio.3001609

Internet

https://doi.org/10.1371/journal.pbio.3001609

Similar Items